NASDAQ:MACK Merrimack Pharmaceuticals (MACK) Stock Price, News & Analysis → **Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! (From Huge Alerts) (Ad) Free MACK Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$15.13▼$15.1350-Day Range$14.65▼$15.1352-Week Range$11.53▼$15.89VolumeN/AAverage Volume396,929 shsMarket Capitalization$223.77 millionP/E Ratio1.09Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial MediaStock AnalysisCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial Media Get Merrimack Pharmaceuticals alerts: Email Address Ad Porter & CompanyObama’s Forever Term [exposed]America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.Start streaming it now at no cost here About Merrimack Pharmaceuticals Stock (NASDAQ:MACK)Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.Read More Ad Porter & CompanyObama’s Forever Term [exposed]America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.Start streaming it now at no cost here MACK Stock News HeadlinesMay 21 at 3:19 AM | americanbankingnews.comMerrimack Pharmaceuticals (NASDAQ:MACK) Upgraded by StockNews.com to "Hold"May 16, 2024 | investorplace.comMACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q1 2024May 15, 2024 | americanbankingnews.comMerrimack Pharmaceuticals (NASDAQ:MACK) Cut to "Sell" at StockNews.comMay 10, 2024 | marketwatch.comMerrimack Pharmaceuticals Shareholders OK Dissolution PlanMay 10, 2024 | businesswire.comMerrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common StockMay 9, 2024 | msn.comMerrimack Pharmaceuticals intends to declare $15.10 dividendMay 9, 2024 | finance.yahoo.comMerrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of DissolutionApril 30, 2024 | businesswire.comMerrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of DissolutionApril 20, 2024 | seekingalpha.comMACK Merrimack Pharmaceuticals, Inc.April 3, 2024 | finance.yahoo.comDiagonal starts up with $128M to make better ‘activator’ antibody drugsMarch 27, 2024 | businesswire.comMerrimack Receives $225 Million Milestone Payment from IpsenMarch 8, 2024 | msn.comStocks Gain as U.S. Unemployment Report Bolsters the Outlook for Fed Rate CutsMarch 8, 2024 | investorplace.comMACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q4 2023March 7, 2024 | businesswire.comMerrimack Reports Full Year 2023 Financial ResultsMarch 4, 2024 | finance.yahoo.comMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is definitely on the radar of hedge funds investors who own 35% of the companyFebruary 22, 2024 | benzinga.comMerrimack Pharmaceuticals Stock (NASDAQ:MACK), Analyst Ratings, Price Targets, PredictionsFebruary 17, 2024 | finance.yahoo.comMACK Mar 2024 14.000 putFebruary 17, 2024 | finance.yahoo.comMACK Mar 2024 4.000 putFebruary 15, 2024 | markets.businessinsider.comOnKure Announces the Appointment of Samuel Agresta, M.D., as Chief Medical OfficerFebruary 14, 2024 | finance.yahoo.comMACK Feb 2024 16.000 putFebruary 14, 2024 | finance.yahoo.comIpsen drug approved by FDA for early pancreatic cancerFebruary 13, 2024 | msn.comThe S&P 500, Dow, Nasdaq are down as traders push back forecasts for interest rate cutsFebruary 13, 2024 | marketwatch.comMerrimack Pharmaceuticals to Hold Meeting on Corporate DissolutionFebruary 13, 2024 | finance.yahoo.comMerrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)February 13, 2024 | businesswire.comMerrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)See More Headlines Receive MACK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Dividend Payable5/17/2024Ex-Dividend for 5/17 Dividend5/20/2024Today5/24/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:MACK Previous SymbolNASDAQ:MACK CUSIP59032810 CIK1274792 Webwww.merrimackpharma.com Phone617-720-8606Fax617-491-1386Employees426Year Founded2000Profitability EPS (Most Recent Fiscal Year)$13.87 Trailing P/E Ratio1.09 Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,180,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1.93% Return on Assets-1.78% Debt Debt-to-Equity RatioN/A Current Ratio10.78 Quick Ratio10.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book11.55Miscellaneous Outstanding Shares14,790,000Free Float10,267,000Market Cap$223.77 million OptionableOptionable Beta1.45 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Gary L. Crocker M.B.A. (Age 72)President, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman Comp: $76kDr. Ulrik B. Nielsen Ph.D. (Age 52)Co-Founder & Independent Director Comp: $72.5kDr. Anthony J. Sinskey Ph.D. (Age 84)Sc.D., Co-Founder and Scientific Advisor Comp: $4.25kMr. Timothy R. Surgenor (Age 64)Secretary Key CompetitorsEmergent BioSolutionsNYSE:EBSRigel PharmaceuticalsNASDAQ:RIGLXOMANASDAQ:XOMAVanda PharmaceuticalsNASDAQ:VNDAVerastemNASDAQ:VSTMView All CompetitorsInsiders & InstitutionsAristides Capital LLCBought 10,000 shares on 5/15/2024Ownership: 0.069%Vanguard Group Inc.Bought 11,893 shares on 5/10/2024Ownership: 4.272%BNP Paribas Financial MarketsBought 2,043 shares on 5/1/2024Ownership: 0.035%Eric AndersenBought 857 shares on 12/28/2023Total: $11,440.95 ($13.35/share)Eric AndersenBought 48,693 shares on 12/26/2023Total: $640,312.95 ($13.15/share)View All Insider TransactionsView All Institutional Transactions MACK Stock Analysis - Frequently Asked Questions When is Merrimack Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our MACK earnings forecast. How were Merrimack Pharmaceuticals' earnings last quarter? Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) released its quarterly earnings results on Wednesday, May, 15th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter. How often does Merrimack Pharmaceuticals pay dividends? What is the dividend yield for Merrimack Pharmaceuticals? Merrimack Pharmaceuticals announced a dividend on Thursday, May 16th. Stockholders of record on Tuesday, May 21st will be paid a dividend of $15.10 per share on Friday, May 17th. This represents a dividend yield of 99.87%. The ex-dividend date of this dividend is Monday, May 20th. This is a positive change from the stock's previous dividend of $1.50. Read our dividend analysis for MACK. When did Merrimack Pharmaceuticals' stock split? Shares of Merrimack Pharmaceuticals reverse split on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Merrimack Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Rite Aid (RAD), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Novavax (NVAX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC) and Verastem (VSTM). Who are Merrimack Pharmaceuticals' major shareholders? Merrimack Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.27%), Aristides Capital LLC (0.07%) and BNP Paribas Financial Markets (0.03%). Insiders that own company stock include Ana Radeljevic, Eric Andersen, Gary L Crocker, Noah G Levy and Ulrik B Nielsen. View institutional ownership trends. This page (NASDAQ:MACK) was last updated on 5/24/2024 by MarketBeat.com Staff From Our PartnersBiden replacement revealed?Paradigm PressUrgent Nvidia WarningAltimetryWrite this ticker symbol down…StocksToTrade**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsMost important medical advance in 100 yearsThe Oxford ClubNew Options need New Trading StrategiesNetpicksExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merrimack Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.